Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy

Current Opinion in Oncology

Volumn 26, Issue 6, 2014, Pages 568-575

  Migliaccio, Ilenia ^a   Di Leo, Angelo ^a   Malorni, Luca ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

Breast cancer therapy; CDK4 6 inhibitors; Predictive biomarkers

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; ANTINEOPLASTIC AGENT; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; ENZYME INHIBITORS; FEMALE; HUMANS;

EID: 84927648589     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000129     Document Type: Review

References (46)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
2. Choi YJ, Anders L. Signaling through cyclin D-dependent kinases. Oncogene 2014; 33:1890-1903.
3. Musgrove EA, Caldon CE, Barraclough J, et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11:558-572.
4. Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div 2012; 7:10.
5. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70.
6. Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pharmacol Ther 2014; 142:258-269.
7. Eeckhoute J, Carroll JS, Geistlinger TR, et al. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 2006; 20:2513-2526.
8. Stender JD, Frasor J, Komm B, et al. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 2007; 21:2112-2123.
9. Kenny FS, Hui R, Musgrove EA, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999; 5:2069-2076.
10. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 1995; 11:885-891.
11. Lundgren K, Brown M, Pineda S, et al. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a transATAC study. Breast Cancer Res 2012; 14:R57.
12. Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep 2002; 9: 409-416.
13. Michalides R, Hageman P, van Tinteren H, et al. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996; 73:728-734.
14. Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating Rb: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer 2011; 18:333-345.
15. Watts CK, Brady A, Sarcevic B, et al. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclindependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995; 9:1804-1813.
16. Carroll JS, Prall OW, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-CDK2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem 2000; 275:38221-38229.
17. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62:233-247.
18. Stendahl M, Kronblad A, Ryden L, et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004; 90:1942-1948.
19. Jirstrom K, Stendahl M, Ryden L, et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res 2005; 65:8009-8016.
20. Miller TW, Balko JM, Fox EM, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011; 1:338-351.
21. Bosco EE, Wang Y, Xu H, et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007; 117:218-228.
22. Massarweh S, Osborne CK, Creighton CJ, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68:826-833.
23. Giessrigl B, Schmidt WM, Kalipciyan M, et al. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer 2013; 109:2751-2762.
24. Sanders DA, Ross-Innes CS, Beraldi D, et al. Genome-wide mapping of foxm1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. Genome Biol 2013; 14:R6.
25. Millour J, Constantinidou D, Stavropoulou AV, et al. FOXM1 is a transcriptional target of eralpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010; 29:2983-2995.
26. Wierstra I, Alves J. Transcription factor FOXM1c is repressed by Rb and activated by cyclin D1/CDK4. Biol Chem 2006; 387:949-962.
27. Anders L, Ke N, Hydbring P, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 2011; 20:620-634.
28. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptorpositive human breast cancer cell lines in vitro. Breast Cancer Res 2009; 11:R77.
29. Koehler M, Vanarsdale TL, Shields D, et al. 60P ∗ Mechanism of action for combined CDK4/6 and ER inhibition in ER positive breast cancer. Ann Oncol 2014; 25 (Suppl. 1):i21.
30. De Michele A, Clark A, Heitjan D, et al. A phase II trial of an oral CDK 4/6 inhibitor, pd0332991, in advanced breast cancer. J Clin Oncol 2013; 31(15-Suppl.):519. May 20 Supplement; 2013 ASCO Annual Meeting Abstracts.
31. Finn RS, Crown JP, Lang I, et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1; TRIO-18) (abstract). In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 April 2014; San Diego, CA/Philadelphia, PA: AACR; 2014. Abstract no. CT101.
32. Patnaik A, Rosen LS, Tolaney SM, et al. Clinical activity of ly2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer (abstract). In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 Apr 2014; San Diego, CA/Philadelphia, PA: AACR; 2014. Abstract no. CT232.
33. Landis MW, Pawlyk BS, Li T, et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006; 9:13-22.
34. Reddy HK, Mettus RV, Rane SG, et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 2005; 65:10174-10178.
35. Yang C, Ionescu-Tiba V, Burns K, et al. The role of the cyclin D1-dependent kinases in ERBB2-mediated breast cancer. Am J Pathol 2004; 164:1031-1038.
36. Knudsen E, Cox D, Franco J, et al. 590 ∗ targeting CDK4/6 in HER2 positive breast cancer: therapeutic effect, markers, and combination strategies. Ann Oncol 2014; 25(Suppl. 1):i21.
37. Roberts PJ, Bisi JE, Strum JC, et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. J Natl Cancer Inst 2012; 104:476-487.
38. Lamb R, Lehn S, Rogerson L, et al. Cell cycle regulators cyclin D1 and CDK4/ 6 have estrogen receptor-dependent divergent functions in breast cancer migration and stem cell-like activity. Cell Cycle 2013; 12:2384-2394.
39. Dean JL, Thangavel C,McClendon AK, et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 2010; 29:4018-4032.
40. Dean JL, McClendon AK, Hickey TE, et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 2012; 11:2756-2761.
41. Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem 2012; 287:29075-29087.
42. McClendon AK, Dean JL, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 2012; 11:2747-2755.
43. Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500mg versus anastrozole 1mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'first' study. Breast Cancer Res Treat 2012; 136:503-511.
44. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 2003; 21:2101-2109.
45. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31:2024-2028.
46. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119:4597-4607.